case_images: PMC5577688_01
case_images: Medication use during treatment with omalizumab in patient 1. Red solid line Omalizumab injections; black solid line Prednisone intake; blue solid line Cetirizine intake; green solid line Ketotifen intake. Average doses of AH and oral glucocorticoids were calculated for every month in the past two and a half years
case_images: 13601_2017_164_Fig1_HTML.jpg
case_images: PMC5577688_01_13601_2017_164_Fig1_HTML.jpg
case_images: Fig1
case_images: Eleven weeks after stopping therapy, facial angioedemas reoccurred (Fig. 1).
case_images: PMC5577688_02
case_images: PMC5577688_03
case_images: Long-term therapy treatment of density of FcepsilonRI-receptors on basophils in patient 1. Red solid line Omalizumab injections; blue solid line FcepsilonRI-receptor density. Receptor density decreased substantially during treatment with omalizumab over 31 months from 74,051 receptors per cell before start of treatment, to 1,907 receptors per cell
case_images: 13601_2017_164_Fig2_HTML.jpg
case_images: PMC5577688_03_13601_2017_164_Fig2_HTML.jpg
case_images: Fig2
case_images: After reintroduction of omalizumab 150 mg at intervals of 4 to 8 weeks over 31 months, the FcepsilonRI-receptor density decreased to a minimal level of 1,907rpc (see Fig. 2).